Germany’s Merck KGaA to Acquire SpringWorks Therapeutics for $3.4 Billion

Germany’s Merck KGaA entered a merger agreement on April 28, 2025, to acquire U.S.-based SpringWorks Therapeutics, Inc. (SWTX) in an all-cash deal valued at $3.4 billion.

Deal Structure:

Under the terms of the agreement, Merck KGaA will acquire SpringWorks for a purchase price of $47 per share in cash, representing a premium of 5.1% from the stock’s last close.

Please subscribe for free or login to your InsideArbitrage account to access this article.